Ionis Pharmaceuticals, Inc.
Modulators of EZH2 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
Status:
Grant
Type:
Utility
Filling date:
11 Apr 2019
Issue date:
21 Jun 2022